论文部分内容阅读
本文测定了33例卵巢癌,41例良性卵巢肿瘤及76例正常人的血清 Cu,Zn 含量及 Cu/Zn比值,结果发现,卵巢癌患者的血清 Cu 含量显著高于良性卵巢肿瘤组及正常对照组;Zn 含量显著低于良性卵巢肿瘤组及正常对照组;Cu/Zn 比值显著高于良性卵巢肿瘤组及正常对照组,并且晚期卵巢癌患者的血 Cu/Zn 比值升高更为显著,用血 Cu/Zn 比值诊断良、恶性卵巢肿瘤的准确性为85%,恶性卵巢肿瘤与正常对照组及良性肿瘤组间阳性预测值分别为92%、92%,特异性分则为97%和95%.本文结果提示血清 Cu、Zn 含量及 Cu/Zn 比值时恶性卵巢肿瘤的辅助诊断,判断预后及在人群中作为卵巢癌的辅助筛选手段具有重要的实用价值.
In this study, we measured the serum levels of Cu, Zn and Cu / Zn in 33 cases of ovarian cancer, 41 cases of benign ovarian tumors and 76 normal subjects. The results showed that the serum Cu levels in patients with ovarian cancer were significantly higher than those in benign ovarian tumors and normal controls Group; Zn content was significantly lower than that of benign ovarian tumor group and normal control group; Cu / Zn ratio was significantly higher than that of benign ovarian tumor group and normal control group, and the serum Cu / Zn ratio of patients with advanced ovarian cancer increased more significantly The accuracy of blood Cu / Zn ratio was 85% for the diagnosis of benign and malignant ovarian tumors, and the positive predictive value was 92% and 92% for malignant ovarian tumors and normal controls and benign tumors respectively, 97% and 95% respectively The results suggest that the serum Cu, Zn content and Cu / Zn ratio of malignant ovarian tumors in the diagnosis, prognosis and in the crowd as an auxiliary screening of ovarian cancer has important practical value.